News and Announcements
Prescient Therapeutics Release Their Prospectus
- Published March 26, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Prescient Therapeutics Prospectus
Fully underwritten non renounceable pro rata entitlement offer of one New Share for every five Existing Shares and one New Option for every two New Shares issued at an offer price of $0.05 per New Share to raise approximately $2.1 million before the exercise of any New Options
Last date for acceptance and payment: 5.00pm (Sydney time) on 23 April 2019
If you are an Eligible Shareholder, this is an important document that requires your immediate attention. It should be read in its entirety. If, after reading this document, you have any questions about the securities being offered for issue under it or any other matter, you should contact your stockbroker, solicitor, accountant or other professional adviser.
This Prospectus also provides for the issue of the Placement Options on the terms announced by the Company on 25 March 2019.
THE ATTACHED DOCUMENT IS IMPORTANT AND SHOULD BE READ IN ITS ENTIRETY
Not for release to US wire services or distribution in the United States
View the Prospectus HERE
View the Letter to Eligible Shareholders Here
View the Letter to Ineligible Shareholders Here
View Letter to Option Holders Here
About Prescient Therapeutics (ASX: PTX, Prescient):
Prescient Therapeutics is developing drugs to treat a range of cancers with significant unmet need. Prescient has one of the deepest clinical pipelines on the ASX, with two drugs that turn off “master switches” that are known to drive cancer.
Exciting interim breast cancer data for PTX-200 has exhibited twice the effectiveness of standard therapy. A new transformative trial for PTX-100 will also soon commence.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
